Abstract 921P
Background
Incidence of oropharyngeal squamous cell carcinoma (OPSCC) increases due to rise in human papilloma virus (HPV) related cancers. The tumor microenvironment (TME) of HPV+ OPSCC is characterized as more immune tolerant, with higher density of tumor-infiltrating lymphocytes (TILs). The role of tumor-associated macrophages (TAMs) remains unclear. M2-like TAMs are correlated with impaired overall survival (OS) in other tumor types. This study characterizes the prognostic impact of M2-like TAMs in OPSCC.
Methods
Fifty-eight patients with primary OPSCC, undergoing definite treatment (surgery, radiotherapy, chemoradiotherapy or a combination), were included. FFPE samples were stained for P16, TILs (CD3, CD8, FOXP3) and TAMs (CD68, CD163 and CD206) markers. Semi-quantitative assessment of each marker, in the tumor nest(t) and stroma(s), was executed by a board certified pathologist. Survival estimates were calculated via the Kaplan-Meier method using the log-rank test, using the ad hoc calculated cut-off point. Uni- and multivariate analysis were performed via cox proportional hazard model.
Results
The median density of sCD3, sCD8, tCD68 and sCD206 TAMs was higher in P16+, compared to P16–, whereas FOXP3 and CD163 infiltration was similar according to P16 status. In univariate analysis, tumors with high leukocyte infiltrates (sTIL, sCD8, tCD8, sFOXP3, tCD68, sCD206) had a better overall survival (OS), whereas sTIL-high and tCD8-high were the only factors associated with DFS. High tCD68 (HR 0.19) and sCD206 (HR 0.40) were associated with improved OS in P16+ OPSCC, but not in P16-. sCD163 and tCD163 infiltration was not related to adverse outcomes in P16+ nor in P16-. Table: 921P
Clinical and immunohistochemical characteristics
| P16- | P16+ | p value | |
| N | 39 | 19 | |
| mean Age (y, SD) | 58.8y (8.0) | 59.8y (8.8) | 0.65 |
| mDFS (months, 95%CI) | 14.4m (7.8-48)* | 158m (30-NR)* | ConclusionsIn this study, high tCD68 and sCD206 expression was associated with a better OS in OPSCC, albeit only in P16+ tumors. No concordance was found between CD163 and CD206 expression and both had a different prognostic impact. This illustrates the complexity of TIL-TAM interplay and the TAM spectrum diversity. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyGhent University Hospital. FundingGhent University Hospital Fonds voor Innovatie en Klinisch Onderzoek (FIKO). DisclosureM. Saerens: Financial Interests, Institutional, Invited Speaker: Pierre-Fabre, BMS, MSD; Financial Interests, Institutional, Advisory Board: Novartis, MSD. S. Rottey: Financial Interests, Institutional, Advisory Board: Pfizer, Merck, Roche, Ipsen, BMS; Financial Interests, Institutional, Invited Speaker: Ipsen, BMS, Astellas; Financial Interests, Institutional, Research Grant: MSD, Roche, BMS; Non-Financial Interests, Principal Investigator, It is my main task in the hospital to attract and perform clinical trials in oncology phase I-III: all companies performing clinical trials in oncology in Europe. All other authors have declared no conflicts of interest. Resources from the same session907P - Biomarker analysis of the phase III KEYNOTE-040 study of pembrolizumab (pembro) versus methotrexate, docetaxel, or cetuximab (SOC) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)Presenter: Denis Soulieres Session: Poster session 03 909P - Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trialPresenter: Alix Marhic Session: Poster session 03 911P - Association of genomic landscape and plasma protein dynamic changes with clinical outcome in patients with R/M HNSCC treated with pembrolizumab with nab-paclitaxel and platinumPresenter: Xinrui Chen Session: Poster session 03 912P - Selection of personalized salvage treatments in advanced refractory head and neck squamous cell carcinomas via multi-omics tumor profilingPresenter: Ramin Ajami Session: Poster session 03 913P - Characterisation of genomic biomarkers of response to cetuximab versus cisplatin in concomitance with radiotherapy in locally advanced squamous head and neck cancerPresenter: Juan Carlos Redondo González Session: Poster session 03 914P - The landscape of somatic copy number alterations of head and neck squamous cell carcinoma across different anatomic sitesPresenter: Juan Carlos Redondo González Session: Poster session 03 915P - Longer OS and RFS for CD3high/PD-L1+ head and neck squamous cell carcinoma (HNSCC) patientsPresenter: Simon Laban Session: Poster session 03 916P - Deep spatial profiling of head and neck squamous cell carcinoma offers insights into the tumor microenvironment of hpv-stratified patientsPresenter: Abhishek Aggarwal Session: Poster session 03 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|